Gertha, EVS, is a rear-view looking mechanism, and as such, presents a small window for evaluating a stock.
For the forward looking investor that is; 5+ years, VRX is quite intriguing. I have a position in VRX, and a larger position in AGN -- the 800 LB gorilla -- leader in this sector.
Allergan will be a big winner and represents the superior play; however, VRX will be a big winner too, by it's mere presence, size and offerings.
There is room for VRX and other players in this sector.
This is a win-win for both; AGN and VRX, in growing and expanding the depth and breadth of the aesthetic and dermatology markets.
Competition doesn't have to be a win-lose proposition folks...
This will be a huge upside for the BIG Players when they both flex their competitive marketing prowess; and it will be immediate!
For the cognoscenti investor, this is like "double-barrel-pin-action" for the foreseeable future.